title: Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
abstract: Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of autologous transplants (38 children, 37 adults) were, respectively: median age, 1.7 and 46 years; non-total body irradiation (non-TBI) conditioning regimen, 97% and 70%; bone marrow as stem cell source, 74% and 43%. Characteristics of the recipients of allogeneic transplants (19 children, 32 adults) were, respectively: median age, 2.8 and 37 years; non-TBI regimen, 63% and 42%; bone marrow as stem cell source, 95% and 69%. Autologous transplantation benefited children more; the relapse rate was high in adults. Results for autologous transplantation were (children and adults, respectively): engraftment, 90% and 100%; 3-year treatment-related mortality (TRM) rate, 3% and 8%; relapse rate, 45% and 64%; leukemia-free survival (LFS) rate, 52% and 27%; overall survival (OS) rate, 61% and 30%. After allogeneic transplantation, TRM was fairly low in children and adults, and relapse rates were lower than after autologous transplantation. Results for allogeneic transplantation were, respectively: engraftment, 95% and 90%; TRM, 0% and 26%; relapse rate, 34% and 28%; LFS, 66% and 46%; OS, 82% and 43%). We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation.
authors.affiliation: Centre International de Greffes, AP-HP, Université Paris VI, Paris, France. laurent.garderet@sat.ap-hop-paris.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Garderet
authors.forename: Myriam
authors.initials: M
authors.lastname: Labopin
authors.forename: Norbert-Claude
authors.initials: NC
authors.lastname: Gorin
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Polge
authors.forename: André
authors.initials: A
authors.lastname: Baruchel
authors.forename: Giovanna
authors.initials: G
authors.lastname: Meloni
authors.forename: Juan
authors.initials: J
authors.lastname: Ortega
authors.forename: Jaak
authors.initials: J
authors.lastname: Vossen
authors.forename: Donald
authors.initials: D
authors.lastname: Bunjes
authors.forename: Guy
authors.initials: G
authors.lastname: Leverger
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Augustin
authors.initials: A
authors.lastname: Ferrant
authors.forename: Mats
authors.initials: M
authors.lastname: Brune
authors.forename: Eric
authors.initials: E
authors.lastname: Dore
authors.forename: Helmut
authors.initials: H
authors.lastname: Gadner
authors.forename: Felix
authors.initials: F
authors.lastname: Zintl
authors.forename: Isaac
authors.initials: I
authors.lastname: Yaniv
authors.forename: Giorgio
authors.initials: G
authors.lastname: Dini
authors.forename: Francesco
authors.initials: F
authors.lastname: Frassoni
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D004314:Down Syndrome / Q000150:complications; D005060:Europe; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007947:Leukemia, Megakaryoblastic, Acute / Q000150:complications / Q000276:immunology / Q000473:pathology* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects